fbpx
A peer-reviewed journal that offers evidence-based clinical information and continuing education for dentists.

Rutgers Receives FDA Approval for Cancer Therapy Clinical Trials

Actinobac Biomed, a company founded by Rutgers School of Dental Medicine researcher Scott Kachlany, PhD, has received U.S. Food and Drug Administration approval to begin a Phase I clinical trial.

0

Actinobac Biomed, a company founded by Rutgers School of Dental Medicine researcher Scott Kachlany, PhD, has received U.S. Food and Drug Administration approval to begin a Phase I clinical trial in patients who have relapsed or refractory leukemia of lymphoma, according to the college.

 

Clinical trials for the drug, leukothera, will begin with 24 patients. This experimental drug kills cancer cells, but does not compromise the immune system. Learn more at newswise.com.

Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

YEAR-END CE SALE

Coupon has expired Get your units by year-end or buy now to get the discount and complete the courses next year. All at discounted pricing!
Get Special CE Savings!